Spliceosomic dysregulation unveils NOVA1 as a candidate actionable therapeutic target in pancreatic neuroendocrine tumors

ALEJANDRO IBÁÑEZ COSTAANTONIO CARLOS FUENTES FAYOSEMILIA Mª ALORS PÉREZJUAN MANUEL JIMÉNEZ VACASJUSTO PASTOR CASTAÑO FUENTESMANUEL DAVID GAHETE ORTIZRAUL MIGUEL LUQUE HUERTASSEBASTIAN EMILIO VENTURA SOTO2025-02-262025-02-26202310.1016/j.trsl.2022.07.0052-s2.0-85136218715https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136218715&doi=10.1016%2fj.trsl.2022.07.005&partnerID=40&md5=34e27ebdf7d115c7e86741b29f1d9ca2https://ucocris.uco.es/handle/123456789/3936Public Health, Environmental and Occupational Health (Q1)Biochemistry (medical) (Q1)Physiology (medical) (Q1)Spliceosomic dysregulation unveils NOVA1 as a candidate actionable therapeutic target in pancreatic neuroendocrine tumorsArticle